Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$54.8 million.

  • Abivax's Consolidated Net Income fell 31.26% to -$54.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$151.6 million, marking a year-over-year decrease of 71.69%. This contributed to the annual value of -$188.3 million for FY2024, which is 18.48% down from last year.
  • Abivax's Consolidated Net Income amounted to -$54.8 million in Q2 2025, which was up 0.52% from -$55.1 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Consolidated Net Income registered a high of -$66.11 during Q4 2022, and its lowest value of -$55.1 million during Q1 2025.
  • For the 3-year period, Abivax's Consolidated Net Income averaged around -$33.0 million, with its median value being -$44.2 million (2024).
  • Data for Abivax's Consolidated Net Income shows a maximum YoY crashed of 107.34% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Abivax's Consolidated Net Income stood at -$66.11 in 2022, then crashed by 107.34% to -$137.07 in 2023, then plummeted by 34.79% to -$184.76 in 2024, then crashed by 31.26% to -$54.8 million in 2025.
  • Its Consolidated Net Income stands at -$54.8 million for Q2 2025, versus -$55.1 million for Q1 2025 and -$184.76 for Q4 2024.